Candel Therapeutics

Immunotherapy
#Cancer research #Candel Therapeutics #Immunotherapy #Solid tumours

Gene delivery evolution: Advancing novel cancer immunotherapies

DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company's cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More

#Cancer Research #Exclusive Content

Non-small cell lung cancer
#Candel Therapeutics #Immunotherapy #Lung cancer #Oncology #Phase II trial

Unique immunotherapy extends survival in advanced NSCLC

Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC).  The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More

#Cancer Research #Editor's Choice #News